Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Public ClinicalTrials.gov record NCT06856577. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (ARTEMIS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an average of Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.
Study identification
- NCT ID
- NCT06856577
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 311 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2025 (Actual)
- Primary completion
- Dec 22, 2026 (Estimated)
- Completion
- Nov 23, 2030 (Estimated)
- Last update posted
- May 22, 2026
2025 – 2030
United States locations
- U.S. sites
- 75
- U.S. states
- 23
- U.S. cities
- 70
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Adverum Clinical Site 223 | Gilbert | Arizona | 85297 | — |
| Adverum Clinical Site 178 | Phoenix | Arizona | 85021 | — |
| Adverum Clinical Site 126 | Phoenix | Arizona | 85053 | — |
| Adverum Clinical Site 229 | Scottsdale | Arizona | 85255 | — |
| Adverum Clinical Site 159 | Tucson | Arizona | 85704 | — |
| Adverum Clinical Site 198 | Springdale | Arkansas | 72764 | — |
| Adverum Clinical Site 109 | Bakersfield | California | 93309 | — |
| Adverum Clinical Site 100 | Beverly Hills | California | 90211 | — |
| Adverum Clinical Site 201 | Campbell | California | 95008 | — |
| Adverum Clinical Site 172 | Encino | California | 91436 | — |
| Adverum Clinical Site 169 | Fullerton | California | 92835 | — |
| Adverum Clinical Site 224 | Huntington Beach | California | 92647 | — |
| Adverum Clinical Site 215 | Redlands | California | 92374 | — |
| Adverum Clinical Site 164 | Riverside | California | 92505 | — |
| Adverum Clinical Site 140 | Sacramento | California | 95825 | — |
| Adverum Clinical Site 212 | Sacramento | California | 95841 | — |
| Adverum Clinical Site 175 | Santa Barbara | California | 93103 | — |
| Adverum Clinical Site 202 | Torrance | California | 90503 | — |
| Adverum Clinical Site 189 | Walnut Creek | California | 94598 | — |
| Adverum Clinical Site 200 | Denver | Colorado | 80222 | — |
| Adverum Clinical Site 116 | Lakewood | Colorado | 80228 | — |
| Adverum Clinical Site 165 | Waterford | Connecticut | 06385 | — |
| Adverum Clinical Site 184 | Deerfield Beach | Florida | 33064 | — |
| Adverum Clinical Site 176 | Fort Lauderdale | Florida | 33308 | — |
| Adverum Clinical Site 221 | Fort Myers | Florida | 33912 | — |
| Adverum Clinical Site 168 | Jacksonville | Florida | 32216 | — |
| Adverum Clinical Site 214 | Lakeland | Florida | 33805 | — |
| Adverum Clinical Site 213 | Orlando | Florida | 32806 | — |
| Adverum Clinical Site 230 | Pensacola | Florida | 32503 | — |
| Adverum Clinical Site 124 | Pompano Beach | Florida | 33064 | — |
| Adverum Clinical Site 183 | South Miami | Florida | 33143 | — |
| Adverum Clinical Site 120 | St. Petersburg | Florida | 33711 | — |
| Adverum Clinical Site 193 | Tampa | Florida | 33617 | — |
| Adverum Clinical Site 182 | Augusta | Georgia | 30909 | — |
| Adverum Clinical Site 179 | Oak Forest | Illinois | 60452 | — |
| Adverum Clinical Site 207 | Oak Park | Illinois | 60304 | — |
| Adverum Clinical Site 195 | Carmel | Indiana | 46032 | — |
| Adverum Clinical Site 205 | Carmel | Indiana | 46032 | — |
| Adverum Clinical Site 197 | Hagerstown | Maryland | 21740 | — |
| Adverum Clinical Site 204 | Hagerstown | Maryland | 21740 | — |
| Adverum Clinical Site 167 | Detroit | Michigan | 48201 | — |
| Adverum Clinical Site 216 | Madison | Mississippi | 39110 | — |
| Adverum Clinical Site 163 | Southaven | Mississippi | 38671 | — |
| Adverum Clinical Site 190 | St Louis | Missouri | 63128 | — |
| Adverum Clinical Site 171 | Teaneck | New Jersey | 07666 | — |
| Adverum Clinical Site 225 | Liverpool | New York | 13088 | — |
| Adverum Clinical Site 196 | Asheville | North Carolina | 28803 | — |
| Adverum Clinical Site 234 | Cary | North Carolina | 27511 | — |
| Adverum Clinical Site 186 | Durham | North Carolina | 27705 | — |
| Adverum Clinical Site 211 | Greensboro | North Carolina | 27401 | — |
| Adverum Clinical Site 220 | Hickory | North Carolina | 28602 | — |
| Adverum Clinical Site 209 | Wake Forest | North Carolina | 27587 | — |
| Adverum Clinical Site 219 | Winston-Salem | North Carolina | 27103 | — |
| Adverum Clinical Site 181 | Erie | Pennsylvania | 16507 | — |
| Adverum Clinical Site 110 | Philadelphia | Pennsylvania | 19107 | — |
| Adverum Clinical Site 208 | Charleston | South Carolina | 29414 | — |
| Adverum Clinical Site 222 | Ladson | South Carolina | 29456 | — |
| Adverum Clinical Site 122 | West Columbia | South Carolina | 29169 | — |
| Adverum Clinical Site 144 | Rapid City | South Dakota | 57701 | — |
| Adverum Clinical Site 123 | Abilene | Texas | 79606 | — |
| Adverum Clinical Site 127 | Austin | Texas | 78705 | — |
| Adverum Clinical Site 108 | Bellaire | Texas | 77401 | — |
| Adverum Clinical Site 227 | Burleson | Texas | 76028 | — |
| Adverum Clinical Site 194 | Dallas | Texas | 75231 | — |
| Adverum Clinical Site 188 | Houston | Texas | 77030 | — |
| Adverum Clinical Site 218 | Katy | Texas | 77494 | — |
| Adverum Clinical Site 162 | McAllen | Texas | 78503 | — |
| Adverum Clinical Site 185 | San Antonio | Texas | 78240 | — |
| Adverum Clinical Site 232 | San Marcos | Texas | 78666 | — |
| Adverum Clinical Site 228 | Schertz | Texas | 78154 | — |
| Adverum Clinical Site 107 | The Woodlands | Texas | 77384 | — |
| Adverum Clinical Site 231 | The Woodlands | Texas | 77384 | — |
| Adverum Clinical Site 199 | Lynchburg | Virginia | 24502 | — |
| Adverum Clinical Site 131 | Spokane | Washington | 99204 | — |
| Adverum Clinical Site 187 | Wausau | Wisconsin | 54403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06856577, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06856577 live on ClinicalTrials.gov.